Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, open-label, single-arm, multicenter clinical study of GAMMAGARD LIQUID in adults with CIDP who developed a relapse in ADVANCE-CIDP 1 trial

Next Previous
Search
Trial Profile

A prospective, open-label, single-arm, multicenter clinical study of GAMMAGARD LIQUID in adults with CIDP who developed a relapse in ADVANCE-CIDP 1 trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Chronic inflammatory demyelinating polyradiculoneuropathy
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ADVANCE-CIDP 2

    • Most Recent Events

    • 01 Feb 2024 New trial record
    • 29 Jan 2024 According to a Takeda media release, company announced that the US FDA has approved GAMMAGARD LIQUID therapy to improve neuromuscular disability and impairment in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) based on results from ADVANCE-CIDP 2 trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top